172 related articles for article (PubMed ID: 37143728)
1. A functional genetic screen for metabolic proteins unveils GART and the
Cipolletti M; Leone S; Bartoloni S; Acconcia F
Front Endocrinol (Lausanne); 2023; 14():1129162. PubMed ID: 37143728
[TBL] [Abstract][Full Text] [Related]
2. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
3. VGLL3 increases the dependency of cancer cells on de novo nucleotide synthesis through GART expression.
Kawamura T; Takehora Y; Hori N; Takakura Y; Yamaguchi N; Takano H; Yamaguchi N
J Cell Biochem; 2022 Jun; 123(6):1064-1076. PubMed ID: 35434822
[TBL] [Abstract][Full Text] [Related]
4. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Acconcia F
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232400
[TBL] [Abstract][Full Text] [Related]
6. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
7. A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.
Cipolletti M; Bartoloni S; Busonero C; Parente M; Leone S; Acconcia F
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805656
[TBL] [Abstract][Full Text] [Related]
8. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
9. Unexpected Impact of a Hepatitis C Virus Inhibitor on 17β-Estradiol Signaling in Breast Cancer.
Bartoloni S; Leone S; Acconcia F
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32408555
[TBL] [Abstract][Full Text] [Related]
10. Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.
Bartoloni S; Pescatori S; Bianchi F; Cipolletti M; Acconcia F
Sci Rep; 2024 Apr; 14(1):8200. PubMed ID: 38589728
[TBL] [Abstract][Full Text] [Related]
11. Zebrafish mutations in gart and paics identify crucial roles for de novo purine synthesis in vertebrate pigmentation and ocular development.
Ng A; Uribe RA; Yieh L; Nuckels R; Gross JM
Development; 2009 Aug; 136(15):2601-11. PubMed ID: 19570845
[TBL] [Abstract][Full Text] [Related]
12. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.
Bauerschmitz G; Hüchel S; Gallwas J; Gründker C
Cancer Genomics Proteomics; 2023; 20(6):531-538. PubMed ID: 37889058
[TBL] [Abstract][Full Text] [Related]
15. Detecting Purinosome Metabolon Formation with Fluorescence Microscopy.
Pedley AM; Benkovic SJ
Methods Mol Biol; 2018; 1764():279-289. PubMed ID: 29605921
[TBL] [Abstract][Full Text] [Related]
16. A high throughput method to study the physiology of E2:ERα signaling in breast cancer cells.
Leone S; Busonero C; Acconcia F
J Cell Physiol; 2018 May; 233(5):3713-3722. PubMed ID: 29091270
[TBL] [Abstract][Full Text] [Related]
17. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
[TBL] [Abstract][Full Text] [Related]
18. GART mediates the renewal of intestinal epithelial barrier via p38/p53/PUMA cascade in colitis.
Bai JA; Jie H; Wei S; Wang S; Guo H; Tang Q
Apoptosis; 2016 Dec; 21(12):1386-1397. PubMed ID: 27718035
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells.
Hany D; Vafeiadou V; Picard D
Sci Adv; 2023 May; 9(19):eadd3685. PubMed ID: 37172090
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]